Core Viewpoint - Lianhua Technology's stock price has seen significant growth this year, with a year-to-date increase of 114.21%, despite a recent decline in trading activity [1] Group 1: Stock Performance - As of November 5, Lianhua Technology's stock price was 11.76 yuan per share, with a market capitalization of 10.717 billion yuan [1] - The stock experienced a net outflow of 29.31 million yuan in principal funds, with large orders showing a buy of 43.25 million yuan and a sell of 61.40 million yuan [1] - The stock has risen by 3.70% in the last five trading days, 7.30% in the last 20 days, and 9.40% in the last 60 days [1] Group 2: Company Overview - Lianhua Technology, established on September 14, 1998, and listed on June 19, 2008, operates in three main sectors: pesticides, pharmaceuticals, and functional chemicals [2] - The revenue composition is as follows: pesticides 54.03%, pharmaceuticals 32.32%, functional chemicals 8.42%, equipment and engineering services 4.88%, and others 0.36% [2] - The company is classified under the basic chemicals industry, specifically in pesticide products [2] Group 3: Financial Performance - For the period from January to September 2025, Lianhua Technology reported a revenue of 4.718 billion yuan, reflecting a year-on-year growth of 8.25% [2] - The net profit attributable to shareholders was 316 million yuan, showing a remarkable year-on-year increase of 871.65% [2] - The company has distributed a total of 960 million yuan in dividends since its A-share listing, with 129 million yuan distributed in the last three years [3]

Group 1 - The company is currently in the technical improvement phase of its lithium hexafluorophosphate project and has not yet generated large-scale sales [1]

Core Viewpoint - The company is currently focused on selling LiFSI and is still in the technical improvement phase for lithium hexafluorophosphate, with no large-scale sales yet [1] Group 1 - The company has received inquiries regarding the mass production of lithium hexafluorophosphate and lithium bis(fluorosulfonyl)imide [1] - The company confirmed that the lithium hexafluorophosphate project is still undergoing technical improvements [1] - There has been no large-scale sales generated from the lithium hexafluorophosphate project as of now [1]

Group 1 - The company, Lianhua Technology, announced that on October 30, 2025, it will accept an investor survey conducted by Bank of China Securities, with senior vice president and secretary Chen Feibiao participating in the reception and addressing investor questions [1] - There have been reports of "negative electricity prices" in multiple regions, raising questions about why power plants are reluctant to shut down despite not making profits from selling electricity [1]

Core Viewpoint - Company is leveraging its long-term expertise in chemical synthesis to enter the new energy sector, focusing on products like electrolytes and advancing customer communication, project development, and quality system construction [1] Group 1 - Company has initiated a review and upgrade of its pipeline product technology to enhance commercial production capacity [1] - The new energy business is expected to achieve significant revenue breakthroughs by 2025 [1] - Future growth will be driven by a large customer strategy, production capacity development, and strengthened quality management [1]

Group 1: New Energy Business Development - The company has focused on chemical synthesis since its establishment and is now entering the new energy sector, leveraging its competitive commercialization capabilities [1] - Current products in the new energy business include electrolytes, with plans for customer communication, project development, and quality system construction [1] - The company aims to achieve a breakthrough in new energy business revenue in 2025, focusing on large customer strategies, enhancing production capabilities, and strengthening quality management [1] Group 2: Pharmaceutical Business Growth - The pharmaceutical business is rapidly developing, primarily through a CDMO model, with partnerships established with several leading global pharmaceutical companies [2] - The company is actively expanding its client base and focusing on strategic, high-viscosity customers, which is expected to drive future growth [2] Group 3: Malaysia Base Development - The product planning for the Malaysia base is centered on crop protection products, with positive feedback from clients regarding the overseas base construction [3] - The Malaysia base is currently in the construction phase, primarily intended for the production of patented crop protection products [3] Group 4: Impact of Tariff Changes - Tariff policies have a limited impact on the company's overall operations, as the export business to the U.S. constitutes a small portion of total operations [4] - The company maintains proactive communication with clients regarding supply chain stability and tax optimization in response to tariff changes [4] Group 5: Capital Expenditure and Funding - Current capital expenditures are focused on the coastal and Malaysia bases, with a net cash flow from operating activities of approximately 900 million yuan in the first three quarters of 2025 [5] - The company aims to gradually reduce its debt-to-asset ratio to lower operational risks and ensure stable operations [5] Group 6: K Amine Product Update - The company continues to provide the advanced intermediate K Amine for chlorantraniliprole under a CDMO model, maintaining a long-term partnership with the client [6] - A long-term framework agreement has been signed for related advanced intermediates, with a pricing model based on cost-plus for stable processing fees [6]

Group 1 - The core point of the announcement is the resolutions passed during the second extraordinary general meeting of shareholders held on October 28, 2025, which included the approval of several key proposals [6][10]. - The meeting was conducted in compliance with relevant laws and regulations, with a combination of on-site and online voting methods [3][5]. - A total of 406 shareholders participated in the voting, representing 33.1097% of the company's total voting shares [4]. Group 2 - The first resolution approved was the change of the purpose of repurchased shares and their cancellation, which received over two-thirds of the votes [6][8]. - The second resolution involved reducing the registered capital and amending the company's articles of association, also passing with over two-thirds support [6][8]. - The company plans to cancel 11,459,900 shares that were repurchased, reducing the registered capital from 911,333,117 yuan to 899,873,217 yuan [12][13]. Group 3 - The company has notified creditors about the reduction in registered capital, allowing them 45 days to request debt repayment or guarantees [13]. - The legal opinions provided by the law firm confirm that the meeting's procedures and voting results are valid and comply with the law [9].

证券代码：002250 证券简称：联化科技 公告编号：2025-052 联化科技股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议时间：2025年10月28日（星期二）15时00分 2、会议地点：上海市黄浦区九江路333号金融广场27楼联化科技会议室 3、会议召集人：联化科技股份有限公司董事会 4、会议方式：现场投票与网络投票相结合的方式 5、会议主持人：董事长王萍女士 6、会议的召集、召开与表决程序符合《公司法》《上市公司股东会规则》《深圳 证券交易所股票上市规则》等法律、法规及规范性文件和《公司章程》的规定。 （二）会议出席情况 出席现场会议的股东共3名，代表有表决权的股份数964,100股，占公司有表决 权股份总数的0.1071%；参加网络投票的股东共403名，代表有表决权的股份数 296,980,936股，占公司有表决权股份总数的33.0025%；参加现场与 ...

联化科技股份有限公司 关于注销已回购股份减少注册资本暨通知债权人的公告 证券代码：002250 证券简称：联化科技 公告编号：2025-053 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）分别于2025年10月9日和2025 年10月28日召开第九届董事会第二次会议和2025年第二次临时股东会，审议通过 了《关于变更回购股份用途并注销的议案》。 公司于2025年3月26日完成回购，公司通过回购专用账户以集中竞价方式累 计回购11,459,900股，占公司总股本的1.26%，成交总金额为79,996,638.00元人民 币（不含交易费用），详见公司于2025年3月28日披露的《关于回购股份比例达到 1%暨回购完成的公告》（公告编号：2025-014）。 本次公司注销已回购股票将涉及公司注册资本减少，根据《中华人民共和国 公司法》（以下简称"《公司法》"）等相关法律、法规的规定，公司特此通知债权 人，债权人自本公告之日起四十五日内，有权要求本公司清偿债务或者提供相应 担保。公司各债权人如要求本公司清偿债务或者提供相应担保 ...

致：联化科技股份有限公司 北京BEIJING·上海SHANGHAI·深圳SHENZHEN·香港HONG KONG·广州GUANGZHOU·西安XI'AN 北京市嘉源律师事务所 关于联化科技股份有限公司 2025年第二次临时股东会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 2025年第二次临时股东会的 法律意见书 嘉源(2025)-04-761 北京市嘉源律师事务所（以下简称"本所"）接受联化科技股份有限公司（以 下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等现行有效的法律、行政法规、部门规章、规范 性文件（以下简称"法律法规"）以及《联化科技股份有限公司章程》（以下简称 "《公司章程》"）的有关规定，指派本所律师对公司2025年第二次临时股东会（以 下简称"本次股东会"）进行见证，并依法出具本法律意见书。 为出具本法律意见书，本所指派律师现场见证了本次股东会，查阅了公司提 供的与本次股东会有关的文件和资料，并进行了必要的核查和验证。在前 ...